Douglas W. Sborov, MD, MS

Journal Article

1. Conry M, Ostrovnaya I, Kemel Y, Sinha S, Baughn LB, Avery B, Maclachlan K, Groner V, Banaszak L, Norman A, Boddicker NJ, Clay-Gilmour A, Kumar S, Kim E, Dandiker S, Waghmare M, Slager S, Sborov DW, Garber J, Brown EE, Hildebrandt M, Hari P, Camp N, Vachon C, Usmani S, Offit K, Joseph (2026). Multiple myeloma risk linked to DNA damage response genes. Journal of hematology & oncology, 19(1), 10.
2. Ailawadhi S, Hansen DK, Dhakal B, Shune LO, Anderson LD Jr, De Braganca KC, Lengil T, Alegria V, Perciavalle M, Lu JH, Sacchi E, Lee S, Emond B, Huo S, Bixby T, Qureshi ZP, Sborov D (2026). FREEDOMM: Fifth-Line or Later Real-World Evaluation of Efficacy and Disease Outcomes in Multiple Myeloma with Ciltacabtagene Autoleucel: Treatment-Free Interval and Overall Survival in the USA. Advances in therapy,
3. Benavente Y, Hermosa S, Papadimitriou N, Clay-Gilmour A, Brown EE, Hofmann JN, Rothman N, Lan Q, Berndt SI, Albanes D, Purdue M, Machiela MJ, Chanock SJ, Bhatti P, Cozen W, Norman A, Slager SL, Cerhan JR, Rajkumar V, Kumar SK, Vachon CM, Novak AJ, Habermann TM, Link BK, Salles G, Ghesquieres H, Bracci PM, Holly E, Griffin RG, Hildebrandt MAT, Vermeulen RCH, Kolijn PM, Hjalgrim H, Smedby KE, Jayasekara H, Cheah S, Monnereau A, Chen Y, Arslan A, Zhang Y, Camp NJ, Sborov DW, Osman AEG, Ziv E, De Vivo I, Joseph V, Teras LR, Patel AV, Kane E, Vajdic CM, Guilloteau A, Cocco P, Alemany L, Sainz J, McKay J, Birmann BM, Casabonne (2026). Circulating levels of insulin-like growth factor I (IGF-I) and risk of multiple myeloma: An observational and Mendelian randomisation study. British journal of haematology,
4. Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri C (2026). Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium. Blood cancer journal, 16(1),
5. Elsey G, Davis JA, Julian K, Gonzalez R, Snyder J, Rice M, Nachar VR, McElwee J, Atrash S, Cahoon C, Bryan B, Sborov DW, Granger K, Warrick M, Dominick A, Hansen DK, Grajales-Cruz A, Mahmoudjafari Z, Rudoni J, Kissam J, Vince M, Khouri J, Ahmed I, Pianko M, Moore D (2026). Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma. European journal of haematology,
6. Rahbari KJ, Galarza Fortuna GM, Dholaria B, Sborov DW, Baljevic (2026). Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myeloma. British journal of haematology,
7. Davis JA, McElwee J, Gonzalez R, Julian K, Nachar VR, Snyder J, Mahmoudjafari Z, Granger K, Warrick M, Smith D, Baek G, Huang I, Portuguese A, Dima D, Banerjee R, Atrash S, Sborov DW, Grajales-Cruz A, Puglianini OC, Dominick A, Hansen DK, Elsey G, Moore D (2026). Safety of MMR vaccination for patients with myeloma receiving daratumumab after autologous stem cell transplantation. Blood neoplasia, 3(2), 100220.
8. Lee HC, Plattel WJ, Harrison SJ, Sborov DW, Lentzsch S, Spencer A, Niesvizky R, Trudel S, Mollee P, Vij R, Minnema MC, Rasche L, Upreti VV, Zhou D, Xia Q, Talpes M, Eggert T, Kapoor P, Ailawadhi (2026). Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma. Blood,
9. Portuguese AJ, Davis JA, Raza S, Castaneda Puglianini O, Freeman C, Alsina M, Wright C, Blue BJ, Baz RC, Shain KH, Goel U, Khouri J, Anwer F, Ali HM, Pasvolsky O, Gaballa M, Patel K, Garcia-Pleitez H, Mikulski D, Fogel L, Zolotov E, Sannareddy A, Afrough A, Anderson LD Jr, Julian K, Dima D, Banerjee R, Liang EC, Cassano Cassano R, Herr MM, Hassan H, Shune L, Kort J, Midha S, Nadeem O, Sidana S, Lin Y, Locke FL, Hansen DK, Sborov D, Biran N, Grajales-Cruz (2026). Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood cancer journal, 16(1),
10. Dona AA, Tandoh T, Nigam L, Singer M, Caserta E, Murtadha M, Zhu Y, Moloudizargari M, Sharma P, Napolitano O, Winchester J, Chowdhury A, Pozhitkov A, Sanchez JF, Vahed H, Marcucci G, Coffey M, Nuovo G, Sborov DW, Pichiorri F, Hofmeister C (2025). Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects. Journal of hematology & oncology, 18(1), 1.
11. Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Ouchveridze E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar AD, Liu Y, Locke FL, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD Jr, Cowan AJ, Kaur (2025). Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Adv. Blood advances,
12. Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Maringanti SA, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S, US Multiple Myeloma Immunotherapy Consortiu (2025). Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology, JCO2500453.
13. Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri C, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo R, Nadeem O, Mann H, Kalariya N, Hovanky V, De Avila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr M, Htut M, McGuirk J, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen D (2025). Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood, 145(1), 85-97.
14. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson P (2025). A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma. Future oncology (London, England), 21(1), 25-49.
15. Badros A, Foster L, Anderson LD Jr, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin TS, Voorhees (2025). Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood, 145(3), 300-310.
16. Dima D, Afrough A, Goel U, Grajales-Cruz A, Khouri J, Julian K, Pasvolsky O, Banerjee R, Razzo B, Ferreri CJ, Vazquez Martinez MA, Davis JA, Sannareddy A, Castaneda Puglianini O, Raza S, Portuguese AJ, Gaballa MR, Rana M, Lieberman-Cribbin A, DeJarnette S, Gonzalez R, Chen A, Herr MM, Mikkilineni L, Hosoya H, Ouchveridze E, Kaur G, Rossi AC, Shune L, Anwer F, Lin Y, Richard S, Sborov DW, Baz RC, Garfall A, Lee HC, Anderson LD Jr, Cowan AJ, Patel KK, Voorhees PM, Sidana S, Hansen DK, Atrash S, Susanibar-Adaniya S (2025). Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment. Blood advances,
17. Li J,Al Faruque H,Li S,Sima M,Sborov D,Hu-Lieskovan S,Werner T,Kope'ek J,Yang (2025). PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer. Journal of controlled release, 382,
18. Singh S, Peshin S, Wertheim BC, Larsen A, Chineke I, Sborov DW, Green D, Liedtke M, Okoniewski M, Wazir M, Nadeem O, Schachter LG, DeGraaff D, Vardell VA, Coffey DG, Gowin (2025). Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study. Haematologica,
19. Rodriguez-Otero P, Voorhees PM, Boccadoro M, Laubach J, Einsele H, Sborov DW, Dimopoulos MA, Broijl A, Mina R, Spencer A, Schjesvold F, Silbermann R, Gay F, Costa LJ, Perrot A, Liu Y, Wang J, Sitthi-Amorn A, Carson R, Cortoos A, Usmani SZ, Richardson PG, Moreau P, Sonneveld P, Kaufman J (2025). Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ¿65 years from GRIFFIN and PERSEUS. Clinical lymphoma, myeloma & leukemia,
20. Pasvolsky O,Dima D,Feng L,Dong W,Richards T,Davis JA,Afrough A,Vazquez-Martinez M,Sannareddy A,Goel U,Banerjee R,Khouri J,Cervoni F,Gaballa MR,Lieberman-Cribbin A,Rana MS,Julian K,Ferreri CJ,Shune L,DeJarnette S,Bhurtel E,Susanibar Adaniya S,Portuguese A,Hosoya H,Mikkilineni L,Kaur G,Rossi A,Herr MM,Schrum D,Lin C,Raza S,Lin Y,Midha S,Omar N,Atarsh S,McGuirk J,Sborov D,Voorhees P,Anwer F,Alsina M,Freeman C,Garfall AL,Razzo BM,Sidana S,Cowan AJ,Anderson LD,Hansen DK,Richard S,Patel KK,Lee HC,Grajales-Cruz (2025). Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood cancer journal, 15(1),
21. Gambles MT,Kendell I,Li J,Spainhower K,Sborov D,Owen S,Stark A,Bearss D,Yang J,Kope'ek (2025). Two-component T-cell immunotherapy enables antigen pre-targeting to reduce cytokine release without forfeiting efficacy. Nanomedicine, 67,
22. Sweiss K,Rodriguez AMA,Quigley JG,Sharp L,Kurzweil K,Sweis JG,Calip GS,Hamilton Z,Uzoka C,Ilo E,Wolf E,Rondelli D,Sborov DW,Patel P,Hofmeister C (2025). Persistent opioid use is associated with a shorter myeloma survival. Supportive care in cancer, 33(5),
23. Rodriguez-Otero P,Voorhees PM,Boccadoro M,Laubach J,Einsele H,Sborov DW,Dimopoulos MA,Broijl A,Mina R,Spencer A,Schjesvold F,Silbermann R,Gay F,Costa LJ,Perrot A,Liu Y,Wang J,Sitthi-Amorn A,Carson R,Cortoos A,Usmani SZ,Richardson PG,Moreau P,Sonneveld P,Kaufman J (2025). Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ¿65 years from GRIFFIN and PERSEUS. Clinical lymphoma, myeloma & leukemia,
24. Li J, Li S, Al Faruque H, Kope'ek J, Sborov DW, Yang (2025). CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma. Biomaterials, 324, 123464.
25. Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen D (2025). Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma. Haematologica,
26. Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, D'Souza A, Szabo A, Mohyuddin G (2025). Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis. Leukemia, 39(9), 2289-2291.
27. Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, Pasvolsky O, Razzo B, Banerjee R, Khouri J, Grajales-Cruz A, Lieberman-Cribbin A, Rana MS, Julian K, DeJarnette S, Portuguese AJ, Gaballa MR, De Avila G, Susaniba Adaniya S, Raza S, Herr MM, Ouchveridze E, Richards T, Hosoya H, Mikkilineni L, Kaur G, Castaneda Puglianini O, Rossi A, Lin Y, Atrash S, Sborov D, Shain KH, Voorhees PM, Richard S, Garfall AL, Hansen DK, Sidana S, Patel KK, Cowan AJ, Anderson LD Jr, Lee HC, Anwer F, Ferreri CJ, Shune (2025). Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood cancer journal, 15(1), 111.
28. Li J, Al Faruque H, Li S, Sima M, Sborov D, Hu-Lieskovan S, Werner T, Kope'ek J, Yang (2025). PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer. Journal of controlled release, 382, 113682.
29. Khouri J, Sborov D, Rossi A, Martin T, Kashyap T, Mark T, Baljevic (2025). Focusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma. Journal of clinical medicine, 14(12),
30. Paul B, Minarik J, Cottini F, Gasparetto C, Khouri J, Gandhi M, Hillengass J, Levy M, Liedtke M, Manda S, Sandhu I, Sborov D, Spicka I, Usmani S, Dong M, Gu L, Leung C, Doshi P, Chen C, Pour (2025). Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma. EJHaem, 6(3), e70072.
31. Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD Jr, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana (2025). Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy. Blood,
32. Mohyuddin GR, Chakraborty R, Berger K, Winborg R, Barnes MS, Hurtado Martinez JA, Hydren JR, Sborov D, Godara A, McClune B, Booth CM, Cliff ER (2025). Patient Preferences on Clinical Decision Making in Multiple Myeloma. JCO oncology practice, OP2500322.
33. Li S, Li J, Faruque HA, Shami P, Knoechel B, Lohr J, Sborov D, Yang J, Kope'ek (2025). Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. Advanced healthcare materials, 14(29), e02156.
34. Galarza Fortuna GM, Peres LC, Nazarenko E, De Menezes Silva Corraes A, Hovanky V, Shune L, McGuirk JP, de Avila G, Khouri J, Dima D, Gaballa MR, Dhakal B, Forsberg PA, Godara A, Afrough A, Anderson LD Jr, Herr MM, Davis JA, Mann H, Purvey S, Clark WB, Htut MM, Beitinjaneh AM, Pereira DL, Kocoglu M, Ferreri CJ, Atrash S, Voorhees PM, Rossi AC, Richard S, Hashmi H, Patel KK, Sidana S, Lin Y, Hansen DK, Sborov D (2025). Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia. Blood advances, 9(23), 6009-6018.
35. Ailawadhi S, Anderson LD Jr, Dhakal B, Shune L, Sborov DW, Hansen D (2025). Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable. Clinical lymphoma, myeloma & leukemia,
36. Maslana KE, Skogerboe GE, Sborov DW, Coletta A (2025). Exercise and Diet Studies Among Patients Living with Multiple Myeloma: Current Evidence and Considerations of Patient Preferences. Frontiers in hematology, 4,
37. Baysal M, Julian K, Sborov D, Godara A, McClune B, Lohr JG, Fortuna GG, Mohyuddin G (2025). The Past, Present and Future of Myeloma Staging and Risk Prognostication. The oncologist, 30(10),
38. Sweiss K, Wagner C, Anto E, Greene T, Sun R, Gonzalez R, Puglianini OC, Freeman C, Ionescu F, Patel K, Ferreri C, Gaballa M, Shune L, McGuirk J, Sidana S, Hovanky V, Khouri J, Raza S, Anwer F, Dima D, Hashmi H, Davis J, Afrough A, Kaur G, Anderson JL, Forsberg P, Herr M, Hansen DK, Hakan Kocoglu M, Sborov (2025). Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium. Transplantation and cellular therapy,
39. Afrough A, Dima D, Razzo B, Goel U, Sannareddy A, Pasvolsky O, Vazquez-Martinez MA, Ferreri CJ, Banerjee R, Khouri J, Davis JA, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Anwer F, Shune L, DeJarnette S, Grajales-Cruz AF, Ouchveridze E, De Avila G, Susanibar-Adaniya SP, Portuguese AJ, Schrum D, Eberwein E, Hosoya H, Mikkilineni L, Kaur G, McGuirk JP, Rossi A, Herr MM, Castaneda O, Locke FL, Raza S, Lin Y, Atrash S, Sborov DW, Voorhees PM, Richard S, Garfall AL, Sidana S, Patel KK, Hansen DK, Cowan AJ, Anderson LD Jr, Lee H (2025). The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience. Blood cancer journal, 16(1), 12.
40. Lee IK, Obata Y, Pomicter AD, Williams JA, Kikani B, Jensen CE, Sborov DW, Stephens DM, Acevedo (2025). Disruption of Marrow Microenvironments in Chronic Lymphocytic Leukemia by High-Resolution Synchrotron Micro-Computed Tomography. bioRxiv,
41. Foster L, Anderson LD Jr, Chung A, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Voorhees P, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin TS, Badros (2025). Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses. Blood cancer journal, 15(1), 154.
42. Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin G (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood cancer journal, 14(1), 20.
43. Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Derman B, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee H, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Snedeker J, Kumar (2024). Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(1D), e240001.
44. Sborov DW, Fortuna GG, Hayden P (2024). Sequence not salvage. British journal of haematology, 204(5), 1590-1592.
45. Hydren JR, Lin D, Sweeney NW, Wu B, Kim N, Patel S, Sborov DW, Berdeja JG, Anderson LD Jr, Huo S, Hurtado Martínez JA, Ahlstrom J (2024). Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group. Frontiers in health services, 4, 1354760.
46. Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees P (2024). Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood cancer journal, 14(1), 69.
47. Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson P (2024). Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood cancer journal, 14(1), 107.
48. Gambles MT, Li S, Kendell I, Li J, Sborov D, Shami P, Yang J, Kope'ek (2024). Multiantigen T-Cell Hybridizers: A Two-Component T-Cell-Activating Therapy. ACS nano, 18(34), 23341-23353.
49. Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson LD Jr, Ferreri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur (2024). Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience. Transplantation and cellular therapy, 30(8), 790.e1-790.e16.
50. Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leukemia & lymphoma, 65(9), 1-4.
51. Mohyuddin GR, Guadamuz J, Ascha M, Chiu BC, Patel P, Sweiss K, Rohrer R, Sborov DW, Calip G (2024). Comparison of patients with myeloma receiving zoledronic acid versus denosumab: A nationwide retrospective cohort study. Blood advances, 8(21), 5539-5541.
52. Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Morán-Segura CM, Nguyen JV, Lekakis L, Fernandez-Pol S, Samraj AN, Naresh KN, Vazquez-Martinez M, Baz RC, Spiegel JY, Mikkilineni L, Gubatan JM, Sidana S, de Menezes Silva Corraes A, Kalariya NM, Patel KK, Shim KG, Fonseca R, Ferreri C, Voorhees PM, Richard S, Valdes CR, Sireesha Asoori, Wolf JL, Cowan AJ, Sborov DW, Locke FL, Lin Y, Wang Y, Hansen D (2024). Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood cancer journal, 14(1), 180.
53. Li P, Alnoor FNU, Xie W, Williams M, Feusier J, Ding Y, Zhao X, Zheng G, Zhao C, Zieske AW, Zu Y, Raess PW, Tantravahi S, Osman A, Patel AB, Tashi T, Patel JL, Matynia AP, Menon MP, Miles RR, Jacobsen JR, George TI, Sborov DW, Szankasi P, Rindler P, Close D, Ohgami R (2024). Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS. Leukemia, 39(1), 248-256.
54. Hydren JR,Lin D,Sweeney NW,Wu B,Kim N,Patel S,Sborov DW,Berdeja JG,Anderson LD,Huo S,Hurtado Martínez JA,Ahlstrom J (2024). Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group. Frontiers in health services, 4,
55. Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina (2024). Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica, 109(5), 1514-1524.
56. Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini O, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri C, Anderson LD Jr, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees P, Khouri J, McGuirk J, Sidana S, Hansen DK, Patel (2024). Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood advances, 8(1), 251-259.
57. Gambles MT, Sborov D, Shami P, Yang J, Kope'ek (2024). Obinutuzumab-Based Drug-Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors. Macromolecular bioscience, 24(3), e2300375.
58. Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen D (2024). Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica, 109(3), 777-786.
59. Silbermann R, Laubach J, Kaufman JL, Sborov DW, Reeves B, Rodriguez C, Chari A, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Orlowski RZ, Shain KH, Cowan AJ, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson P (2024). Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. American journal of hematology, 99(7), 1257-1268.
60. Zanwar S, Galarza Fortuna GM, Sborov D (2024). Risk-adapted treatment in multiple myeloma: Does more make it merrier?. British journal of haematology, 205(3), 767-769.
61. Li J, Cho YK, Sborov DW, Phelps MA, Hofmeister CC, Poi M (2023). Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant. Cancer genomics & proteomics, 20(1), 9-17.
62. Paul B, Liedtke M, Khouri J, Rifkin R, Gandhi MD, Kin A, Levy MY, Silbermann R, Cottini F, Sborov DW, Sandhu I, Villarreal L, Murphy M, Gu L, Chen A, Rajakumaraswamy N, Usmani S (2023). A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma. Future oncology (London, England), 19(1), 7-17.
63. Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jiménez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, García-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio J (2023). Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nature medicine, 29(4), 869-879.
64. Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Rosenberg A, Sborov D, Valent J, Berardi R, Kumar (2023). Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21(1), 67-81.
65. Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini O (2023). Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood cancer journal, 13(1), 117.
66. Trunk AD, Patel SS, Prchal JT, Sborov DW, Zander AR, Lee C (2023). Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide. Leukemia research reports, 20, 100388.
67. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson P (2023). Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. The Lancet. Haematology, 10(10), e825-e837.
68. Hentzen S, Meirson T, Koehn K, Goodman A, Chakraborty R, Sborov D, Rubinstein S, Mohyuddin G (2023). Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review. European journal of haematology, 111(3), 491-498.
69. Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker (2023). Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21(12), 1281-1301.
70. Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin G (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA network open, 6(11), e2342195.
71. Trunk AD,Patel SS,Prchal JT,Sborov DW,Zander AR,Lee C (2023). Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide. Leukemia research reports, 20,
72. Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortüm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial (2023). Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer, 129(23), 3746-3760.
73. Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, Ahmed N, Hashmi (2023). Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplantation and cellular therapy, 29(9), 567-571.
74. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin G (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leukemia & lymphoma, 64(7), 1340-1343.
75. Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. Clinical hematology international, 5(2-3), 170-176.
76. Griffin R, Hanson HA, Avery BJ, Madsen MJ, Sborov DW, Camp N (2023). Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes. Cancer epidemiology, biomarkers & prevention, 32(5), 708-717.
77. Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel K (2023). Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. Journal of clinical oncology, 41(11), 2087-2097.
78. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin G (2023). Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology, 200(5), 587-594.
79. Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD Jr, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees P (2023). Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplantation and cellular therapy, 29(3), 174.e1-174.e10.
80. Li J, Persaud AK, Johnson JA, Sborov DW, Phelps MA, Hofmeister CC, Poi M (2022). A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. Anticancer research, 42(1), 385-395.
81. Baljevic M, Sborov DW, Lim MY, Hillengass J, Martin T, Castillo JJ, Streiff MB, Kumar SK, Callander N (2022). Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma. Journal of the National Comprehensive Cancer Network, 20(1), 91-95.
82. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin G (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. European journal of cancer (Oxford, England, 167, 152-160.
83. Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin G (2022). Financial toxicity in hematological malignancies: a systematic review. Blood cancer journal, 12(4), 74.
84. Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar S (2022). NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. Journal of the National Comprehensive Cancer Network, 20(1), 8-19.
85. Fatoki RA,Koehn K,Kelkar A,Al Hadidi S,Mehra N,Mian H,Landgren O,Kazandjian D,Hoffman J,Sborov DW,Mohyuddin G (2022). Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO global oncology, 8, e2200119.
86. McInturf G,Younger K,Sanchez C,Walde C,Abdallah AO,Ahmed N,Shune L,Sborov DW,Godara A,McClune B,Sinclair CT,Mohyuddin G (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. European journal of haematology,
87. Steinbach M,Julian K,McClune B,Sborov D (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Therapeutic advances in hematology, 13,
88. Tommy Gambles M,Li J,Christopher Radford D,Sborov D,Shami P,Yang J,Kope'ek (2022). Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo. Journal of controlled release, 350, 584-599.
89. Robert A. Campbell,1 Bhanu Kanth Manne,1 Meenakshi Banerjee,1 Elizabeth A. Middleton,1 Abigail Ajanel,2 Hansjorg Schwertz,1 Frederik Denorme,1 Chris Stubben,3 Emilie Montenont,1 Samantha Saperstein,1 Lauren Page,1 Neal D. Tolley,1 Diana L. Lim,1 Samuel M. Brown,4 Colin K. Grissom,4 Douglas W. Sborov,5 Anandi Krishnan,6 and Matthew T. Rondina (2022). IFITM3 regulates fibronogen endocytosis and platelet reactivity in non-viral sepsis. The Journal of clinical investigation, 2022(1),
90. Sonja I. Berndt, Joseph Vijai, Yolanda Benavente, Nicola J. Camp, Alexandra Nieters, Zhaoming Wang, Karin E. Smedby, Geffen Kleinstern, Henrik Hjalgrim, Caroline Besson, Christine F. Skibola, Lindsay M. Morton, Angela R. Brooks-Wilson, Lauren R. Teras, Charles Breeze, Joshua Arias, Hans-Olov Adami, Demetrius Albanes, Kenneth C. Anderson, Stephen M. Ansell, Bryan Bassig, Nikolaus Becker, Parveen Bhatti, Brenda M. Birmann, Paolo Boffetta, Paige M. Bracci, Paul Brennan, Elizabeth E. Brown, Laurie Burdett, Lisa A. Cannon-Albright, Ellen T. Chang, Brian C. H. Chiu, Charles C. Chung, Jacqueline Clavel, Pierluigi Cocco, Graham Colditz, Lucia Conde, David V. Conti, David G. Cox, Karen Curtin, Delphine Casabonne, Immaculata De Vivo, W. Ryan Diver, Ahmet Dogan, Christopher K. Edlund, Lenka Foretova, Joseph F. Fraumeni Jr, Attilio Gabbas, Hervé Ghesquières, Graham G. Giles, Sally Glaser, Martha Glenn, Bengt Glimelius, Jian Gu, Thomas M. Habermann, Christopher A. Haiman, Corinne Haioun, Jonathan N. Hofmann, Theodore R. Holford, Elizabeth A. Holly, Amy Hutchinson, Aalin Izhar, Rebecca D. Jackson, Ruth F. Jarrett, Rudolph Kaaks, Eleanor Kane, Laurence N. Kolonel, Yinfei Kong, Peter Kraft, Anne Kricker, Annette Lake, Qing Lan, Charles Lawrence, Dalin Li, Mark Liebow, Brian K. Link, Corrado Magnani, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Roger L. Milne, Thierry J. Molina, Alain Monnereau, Rebecca Montalvan, Kari E. North, Anne J. Novak, Kenan Onel, Mark P. Purdue, Kristin A. Rand, Elio Riboli, Jacques Riby, Eve Roman, Gilles Salles, Douglas W. Sborov, Richard K. Severson, Tait D. Shanafelt, Martyn T. Smith, Alexandra Smith, Kevin W. Song, Lei Song, Melissa C. Southey, John J. Spinelli, Anthony Staines, Deborah Stephens, Heather J. Sutherland, Kaitlyn Tkachuk, Carrie A. Thompson, Hervé Tilly, Lesley F. Tinker, Ruth C. Travis, Jenny Turner, Celine M. Vachon, Claire M. Vajdic, Anke Van Den Berg, David J. Van Den Berg, Roel C. H. Vermeulen, Paolo Vineis, Sophia S. Wang, Elisabete Weiderpass, George J. Weiner, Stephanie Weinstein, Nicole Wong Doo, Yuanqing Ye, Meredith Yeager, Kai Yu, Anne Zeleniuch-Jacquotte, Yawei Zhang, Tongzhang Zheng, Elad Ziv, Joshua Sampson, Nilanjan Chatterjee, Kenneth Offit, Wendy Cozen, Xifeng Wu, James R. Cerhan, Stephen J. Chanock, Susan L. Slager & Nathaniel Rothma (2022). Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. American journal of leukemia research, 2022, 1-10.
91. Victoria A. Vardell,Daniel A. Ermann,Srinivas K. Tantravahi,Benjamin Haaland,Brian McClune,Amandeep Godara,Ghulam Rehman Mohyuddin,Douglas W Sboro (2022). Impact of academic medical center access on outcomes in multiple myeloma. American journal of hematology, 2022, 1-8.
92. Ghulam Rehman Mohyuddin Jennifer M Ahlstrom Cindy A Chmielewski Nathan W Sweeney Thomas H Molina Christian S Cheung Emily Watabe Ballard Felicia F Seng Oliver Van Oekelen Amandeep Godara Brian McClune Douglas Sboro (2022). A survey on the patient perspective on cure in multiple myeloma. . The Lancet. Haematology, 9(10), E716-E719.
93. Kellen Gil, Saqib Abbasi, Kathan Mehta, Brian McClune, Douglas Sborov, Nausheen Ahmed, Al-Ola Abdallah, Siddhartha Ganguly, Joseph McGuirk, Leyla Shune & Ghulam Rehman Mohyuddi (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clinical hematology international, 4((2022)), 56-59.
94. Mohammad Ahsen Soomro,James Hoffman,Aaron Michael Goodman,Douglas Weston Sborov,Ghulam Rehman Mohyuddi (2022). Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials. . British journal of haematology, 197(6), e86-e88.
95. Campbell RA,Manne BK,Banerjee M,Middleton EA,Ajanel A,Schwertz H,Denorme F,Stubben C,Montenont E,Saperstein S,Page L,Tolley ND,Lim DL,Brown SM,Grissom CK,Sborov DW,Krishnan A,Rondina M (2022). IFITM3 regulates fibrinogen endocytosis and platelet reactivity in nonviral sepsis. The Journal of clinical investigation, 132(23),
96. Berndt SI,Vijai J,Benavente Y,Camp NJ,Nieters A,Wang Z,Smedby KE,Kleinstern G,Hjalgrim H,Besson C,Skibola CF,Morton LM,Brooks-Wilson AR,Teras LR,Breeze C,Arias J,Adami HO,Albanes D,Anderson KC,Ansell SM,Bassig B,Becker N,Bhatti P,Birmann BM,Boffetta P,Bracci PM,Brennan P,Brown EE,Burdett L,Cannon-Albright LA,Chang ET,Chiu BCH,Chung CC,Clavel J,Cocco P,Colditz G,Conde L,Conti DV,Cox DG,Curtin K,Casabonne D,De Vivo I,Diver WR,Dogan A,Edlund CK,Foretova L,Fraumeni JF,Gabbas A,Ghesquières H,Giles GG,Glaser S,Glenn M,Glimelius B,Gu J,Habermann TM,Haiman CA,Haioun C,Hofmann JN,Holford TR,Holly EA,Hutchinson A,Izhar A,Jackson RD,Jarrett RF,Kaaks R,Kane E,Kolonel LN,Kong Y,Kraft P,Kricker A,Lake A,Lan Q,Lawrence C,Li D,Liebow M,Link BK,Magnani C,Maynadie M,McKay J,Melbye M,Miligi L,Milne RL,Molina TJ,Monnereau A,Montalvan R,North KE,Novak AJ,Onel K,Purdue MP,Rand KA,Riboli E,Riby J,Roman E,Salles G,Sborov DW,Severson RK,Shanafelt TD,Smith MT,Smith A,Song K (2022). Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia, 36(12), 2835-2844.
97. Sborov DW,Baljevic M,Reeves B,Laubach J,Efebera YA,Rodriguez C,Costa LJ,Chari A,Silbermann R,Holstein SA,Anderson LD,Kaufman JL,Shah N,Pei H,Patel S,Cortoos A,Bartlett JB,Vermeulen J,Lin TS,Voorhees PM,Richardson P (2022). Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. British journal of haematology, 199(3), 355-365.
98. Mohyuddin GR,Ahlstrom JM,Chmielewski CA,Sweeney NW,Molina TH,Cheung CS,Ballard EW,Seng FF,Van Oekelen O,Godara A,McClune B,Sborov (2022). A survey on the patient perspective on cure in multiple myeloma. The Lancet. Haematology, 9(10), e716-e719.
99. Vardell VA,Ermann DA,Tantravahi SK,Haaland B,McClune B,Godara A,Mohyuddin GR,Sborov D (2022). Impact of academic medical center access on outcomes in multiple myeloma. American journal of hematology,
100. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin G (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. European journal of haematology, 109(5), 559-565.
101. Steinbach M, Julian K, McClune B, Sborov D (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Therapeutic advances in hematology, 13, 20406207221100659.
102. Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin G (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clinical hematology international, 4(1-2), 56-59.
103. Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S (2021). The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol, 96(7), 846-853.
104. Mohyuddin GR, Koehn K, Abdallah AO, Sborov D, Rajkumar SV, Kumar S, McClune B (2021). Use of Endpoints in Multiple Myeloma Randomized Controlled Trials over the Last Fifteen Years: A Systematic Review. Am J Hematol, 96(6), 690-697.
105. Waller RG, Klein RJ, Vijai J, McKay JD, Clay-Gilmour A, Wei X, Madsen MJ, Sborov DW, Curtin K, Slager SL, Offit K, Vachon CM, Lipkin SM, Dumontet C, Camp NJ (2021). Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. Hum Mol Genet, 30(12), 1142-1153.
106. Collier KA, Valencia H, Newton H, Hade EM, Sborov DW, Cavaliere R, Poi M, Phelps MA, Liva SG, Coss CC, Wang J, Khountham S, Monk P, Shapiro CL, Piekarz R, Hofmeister CC, Welling DB, Mortazavi (2021). A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer chemotherapy and pharmacology, 87(5), 599-611.
107. Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, Ghoda L, Gunes EG, Sanchez JF, Khalife J, Martella M, Karanes C, Htut M, Wang X, Rosenzweig M, Chowdhury A, Sborov D, Miles RR, Yazaki PJ, Ebner T, Hofmeister CC, Forman SJ, Rosen ST, Marcucci G, Shively J, Keats JJ, Krishnan A, Pichiorri (2021). Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia, 35(1), 189-200.
108. Usmani SZ, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson P (2021). Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia, 35, 3526-3533.
109. Abbasi S, Roller J, Abdallah AO, Shune L, McClune B, Sborov D, Mohyuddin G (2021). Hospitalization at the end of life in patients with multiple myeloma. BMC cancer, 21(1), 339.
110. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami P (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC cancer, 21(1), 510.
111. M. Tommy Gambles, Jiahui Li, Jiawei Wang, Douglas Sborov, Jiyuan Yang *, Jind'ich Kope'e (2021). Crosslinking of CD38 receptors triggers apoptosis of malignant B cells. Molecules (Basel, Switzerland), Applied Chemistry Section, Vol. 26(14),
112. Lonial S, Nooka AK, Thulasi P, Badros AZ, Jeng BH, Callander NS, Potter HA, Sborov D, Zaugg BE, Popat R, Degli Esposti S, Byrne J, Opalinska J, Baron J, Piontek T, Gupta I, Dana R, Farooq AV, Colby K, Jakubowiak (2021). Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood cancer journal, 11(5), 103.
113. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad (2021). Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. The Lancet. Haematology, 8(4), e299-e304.
114. Ghose J, Dona A, Murtadha M, Gunes EG, Caserta E, Yoo JY, Russell L, Jaime-Ramirez AC, Barwick BG, Gupta VA, Sanchez JF, Sborov DW, Rosen ST, Krishnan A, Boise LH, Kaur B, Hofmeister CC, Pichiorri (2021). Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. Molecular therapy oncolytics, 20, 519-531.
115. Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar S (2021). Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood advances, 5(4), 1097-1101.
116. Sagar Lonial MD, Hans C. Lee MD, Ashraf Badros MD, Suzanne Trudel MD, Ajay K. Nooka MD, Ajai Chari MD, Al-Ola Abdallah MD, Natalie Callander MD, Douglas Sborov MD, Attaya Suvannasankha MD, Katja Weisel MD, Peter M. Voorhees MD, Lynsey Womersley MSc, January Baron MS, Trisha Piontek BSN, Eric Lewis MD, Joanna Opalinska MD, Ira Gupta MD, Adam D. Cohen M (2021). Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. July2021(https://doi.org/10.1002/cncr.33809),
117. Griffin Waller R, Madsen MJ, Gardner J, Sborov DW, Camp N (2021). Duo Shared Genomic Segment analysis identifies a genome-wide significant risk locus at 18q21.33 in myeloma pedigrees. 5(2), 112-123.
118. Gambles MT, Li J, Wang J, Sborov D, Yang J, Kope'ek (2021). Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells. Molecules (Basel, Switzerland), 26(15),
119. Ghose J,Dona A,Murtadha M,Gunes EG,Caserta E,Yoo JY,Russell L,Jaime-Ramirez AC,Barwick BG,Gupta VA,Sanchez JF,Sborov DW,Rosen ST,Krishnan A,Boise LH,Kaur B,Hofmeister CC,Pichiorri (2021). Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. Molecular therapy oncolytics, 20, 519-531.
120. Waller RG,Madsen MJ,Gardner J,Sborov DW,Camp N (2021). Duo Shared Genomic Segment analysis identifies a genome-wide significant risk locus at 18q21.33 in myeloma pedigrees. Journal of translational genetics and genomics, 5(2), 112-123.
121. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG (2020). Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 136(8), 936-945.
122. Sharma N, Chen DT, Zhao Q, Williams NY, Rosko A, Benson DM, Chaudhry M, Bumma N, Khan A, Devarakonda S, Hofmeister CC, Sborov D, Efebera Y (2020). Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. Biology of blood and marrow transplantation, 26(1), 44-49.
123. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen A (2020). Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. The Lancet. Oncology, 21(2), 207-221.
124. Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar (2020). Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(12), 1685-1717.
125. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby (2020). Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and therapy, 9(4), 889-911.
126. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby (2020). Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and therapy, 9(4), 913-915.
127. Farooq AV,Degli Esposti S,Popat R,Thulasi P,Lonial S,Nooka AK,Jakubowiak A,Sborov D,Zaugg BE,Badros AZ,Jeng BH,Callander NS,Opalinska J,Baron J,Piontek T,Byrne J,Gupta I,Colby (2020). Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody'Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study (Ophthalmology and Therapy, (2020), 9, 4, (889-911), 10.1007/s40123-020-00280-8). Ophthalmology and therapy, 9(4), 913-915.
128. Farooq AV,Degli Esposti S,Popat R,Thulasi P,Lonial S,Nooka AK,Jakubowiak A,Sborov D,Zaugg BE,Badros AZ,Jeng BH,Callander NS,Opalinska J,Baron J,Piontek T,Byrne J,Gupta I,Colby (2020). Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody'Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and therapy, 9(4), 889-911.
129. Peter M. Voorhees, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Jr, Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S. Lin, Paul G. Richardso (2020). GRIFFIN Trial Investigators. (2020). Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 136(8), 936-945. Blood, 136(8), 936-945.
130. Domenico Viola, Ada Dona, Enrico Caserta, Estelle Troadec, Francesca Besi, Tinisha McDonald, Lucy Ghoda, Emine Gulsen Gunes, James F. Sanchez, Jihane Khalife, Marianna Martella, Chatchada Karanes, Myo Htut, Xiuli Wang, Michael Rosenzweig, Arnab Chowdhury, Douglas Sborov, Rodney R. Miles, Paul J. Yazaki, Todd Ebner, Craig C. Hofmeister, Stephen J. Forman, Steven T. Rosen, Guido Marcucci, John Shively, Jonathan J. Keats, Amrita Krishnan & Flavia Pichiorr (2020). Daratumumab Induces Mechanisms of Immune activation through CD38+ NK Cell targeting. Leukemia, 35, 189-200.
131. Poi MJ, Li J, Johnson JA, Cho YK, Sborov DW, Phelps MA, Hofmeister CC (2019). A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer Res, 39(1), 67-72.
132. Persaud AK, Li J, Johnson JA, Seligson N, Sborov DW, Duah E, Cho YK, Wang D, Phelps MA, Hofmeister CC, Poi MJ (2019). XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. Mol Carcinog, 58(12), 2327-2339.
133. Kumar SK1, Callander NS2, Hillengass J3, Liedtke M4, Baljevic M5, Campagnaro E6, Castillo JJ7, Chandler JC8, Cornell RF9, Costello C10, Efebera Y11, Faiman M12, Garfall A13, Godby K14, Holmberg L15, Htut M16, Huff CA17, Kang Y18, Landgren O19, Malek E12, Martin T20, Omel J21, Raje N22, Sborov D23, Singhal S24, Stockerl-Goldstein K25, Tan C26, Weber D27, Johnson-Chilla A28, Keller J28, Kumar R28 (2019). NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Journal of the National Comprehensive Cancer Network,
134. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar (2019). NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Journal of the National Comprehensive Cancer Network, 17(10), 1154-1165.
135. Cho YK, Irby DJ, Li J, Sborov DW, Mould DR, Badawi M, Dauki A, Lamprecht M, Rosko AE, Fernandez S, Hade EM, Hofmeister CC, Poi M, Phelps M (2018). Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant. CPT, 7(11), 748-758.
136. Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, Phelps MA, Hofmeister CC (2017). Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Mol Carcinog.
137. Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, Phelps MA, Hofmeister CC (2017). Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Mol Carcinog, 56(7), 1722-1732.
138. Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC (2017). A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma, 58(10), 2310-2318.
139. Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps M (2017). Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial. Clinical pharmacology and therapeutics, 102(3), 511-519.
140. Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Phelps MA, Hofmeister C (2017). Construction of a personalized PK melphalan model in the setting of a randomized cryotherapy trial in multiple myeloma patients undergoing autologous stem cell transplantation. Clinical pharmacology and therapeutics,
141. Mezache L, Magro C, Hofmeister C, Pichiorri F, Sborov D, Nuovo G (2017). Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions. Applied immunohistochemistry & molecular morphology, 25(2), 100-109.
142. Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri (2016). Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Molecular cancer therapeutics, 15(5), 830-41.
143. Sborov DW, Benson DM, Williams N, Huang Y, Bowers MA, Humphries K, Efebera Y, Devine S, Hofmeister CC (2015). Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. Br J Haematol, 171(1), 74-83.
144. Sborov D, Chen J (2015). Targeted therapy in sarcomas other than GIST tumors. Journal of surgical oncology, 111(5), 632-40.
145. Sborov DW, Haverkos BM, Harris P (2015). Investigational cancer drugs targeting cell metabolism in clinical development. Expert opinion on investigational drugs, 24(1), 79-94.
146. Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri (2015). HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget, 6(31), 31134-50.
147. Sborov D,Haverkos B,Harris (2015). Investigational cancer drugs targeting cell metabolism in clinical development. Expert opinion on investigational drugs, 24(1), 79-94.
148. Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister C (2014). A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clinical cancer research, 20(23), 5946-55.

Review

1. Maslana KE,Skogerboe GE,Sborov DW,Coletta A (2025). Exercise and diet studies among patients living with multiple myeloma: current evidence and considerations of patient preferences. Frontiers in hematology, 4,
2. Zhukovsky S, White J, Chakraborty R, Costa LJ, Van Oekelen O, Sborov DW, Cliff ERS, Mohyuddin G (2024). Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria. Leukemia & lymphoma, 1-10.
3. Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin G (2023). Multiple Myeloma in Young Patients: A Scoping Review. Clinical lymphoma, myeloma & leukemia, 24(1), 15-22.
4. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. European journal of cancer (Oxford, England, 156, 164-174.
5. Sborov DW, Rodgers GM (2013). How I manage patients with acquired haemophilia A. [Review]. Br J Haematol, 161, (2), 157-65.
6. Sborov DW, Rodgers G (2012). Acquired hemophilia a: a current review of autoantibody disease. Clinical advances in hematology & oncology, 10(1), 19-27.

Book Chapter

1. Sborov DW, Rodgers G (2014). Postoperative Strategies for Resumption of Anticoagulants and Antiplatelet Agents in Neurosurgical Patients.

Conference Proceedings

1. Sieverts M,Rabbitt N,Parkinson DY,Sborov DW,Acevedo (2022). Multi-Tissue Analysis Using Synchrotron Radiation Micro-CT Images. Proceedings - 2022 IEEE 18th International Conference on e-Science, eScience 2022, 74-83.

Commentary

1. Sborov, D (2022). Sborov DW. A commentary on: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. PracticeUpdate website. Available at:https://www.practiceupdate.com/content/defining-new-reference-intervals-for-serum-free-light-chains-in-individuals-with-chronic-kidney-disease/141995/65/1/1. Accessed October 11, 2022. PracticeUpdate Website,

Editorial

1. Baljevic M, Sborov DW, Kumar S (2024). Long term responders in frontline multiple myeloma-exception vs expectation of the modern era. Blood cancer journal, 14(1), 115.
2. Baljevic M, Sborov D (2023). Understanding risks and refining strategies for thromboembolism prophylaxis in hematopoietic stem cell transplant recipients. Bone marrow transplantation,

Letter

1. Galarza Fortuna GM, Rahbari KJ, Baljevic M, Sborov D (2026). "Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT": comment from Galarza Fortuna et al. Journal of thrombosis and haemostasis, 24(1), 337-340.
2. Rees MJ, Khouri J, Grajales-Cruz AF, Zanwar SS, Goel U, Midha S, Kelley J, Puglianini OC, Corraes AMS, Raza S, Davis JA, Green K, Hansen DK, Banerjee R, Sidana S, Patel KK, Bianchi G, Sborov DW, Lee S, Kumar SK, Baz R, Anwer F, Mikkilineni L, Nadeem O, Lin Y, Anderson LD J (2026). The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis. American journal of hematology, 101(1), 187-192.
3. Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD Jr, Lin (2024). Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood cancer journal, 14(1), 63.
4. Mohyuddin GR, Rubinstein SM, Kumar S, Rajkumar SV, Fonseca R, Abdallah NH, Calip GS, Wang X, Parrinello CM, Sborov (2024). Performance of newer myeloma staging systems in a contemporary, large patient cohort. Blood cancer journal, 14(1), 95.
5. Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen D (2024). Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. Journal of hematology & oncology, 17(1), 42.
6. Soomro MA, Hoffman J, Goodman AM, Sborov DW, Mohyuddin G (2022). Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials. British journal of haematology, 197(6), e86-e88.
7. Zhang Y,Godara A,Pan S,Toskic D,Mann H,Sborov D,Comenzo R,Kansagra (2022). Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma. Annals of hematology, 101(9), 2119-2121.
8. Mohyuddin GR, Chakraborty R, Calip GS, Ascha MS, Wang X, Rubinstein SM, Tuchman S, Costa L, Haaland B, Giri S, Mian H, Fonseca R, Sborov (2022). Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. Blood cancer journal, 12(12), 168.
9. Gil K,Abbasi S,Mehta K,McClune B,Sborov D,Ahmed N,Abdallah AO,Ganguly S,McGuirk J,Shune L,Mohyuddin G (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clinical hematology international, 4(1-2), 56-59.
10. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens (2020). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. Leukemia, 34(1), 317-321.
11. John S, Sharma N, Sborov DW, Williams N, Jones D, Benson DM, Efebera YA, Rosko AE, Vincent J, Hofmeister CC (2018). Most multiple myeloma patients have low testosterone. [Letter to the editor]. Leuk Lymphoma, 60(3), 836-838.
12. Sborov DW, Cho YK, Cottini F, Hade EM, Lamprecht M, Tackett K, Sharma N, Williams N, Li J, Devine S, Poi M, Phelps MA, Hofmeister CC (2017). G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. [Letter to the editor]. Leuk Lymphoma, 58(12), 2947-2951.

Abstract

1. Hang Quach, Doug Sborov, Dickran Kazandjian, Andrew Spencer, Michael Low, Susan Bal, Natalie S. Callander, Huan Cheng, Sheel Patel, Rocco J. Crescenzo, Amit Agarwal and Binod Dhakal (2023). Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14) : Safety, Efficacy, and Determination of Recommended Phase 2 Dose. ASH- San Diego, CA.
2. Ghulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kunnathu Kumar, S. Vincent Rajkumar, Rafael Fonseca, Nadine Abdallah, Greg Calipan, Xiaoyan Wan, Christina Parrinello and Doug Sboro (2023). Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States. ASH- San Diego, CA.
3. Jenny S. Guadamuz; Rebecca Rohrer; Ghulam Rehman Mohyuddin; Brian C.-H. Chiu; Pritesh R. Patel; Karen Sweiss; Erlene Seymour; Douglas Sborov; Gregory S. Cali (2022). Abstract 3669: Racial/ethnic disparities in treatment with bone-modifying agents among newly diagnosed multiple myeloma patients. . 82(12 (Supplement)), 3669.
4. Rafael Fonseca, Junya Kuroda, Tadao Ishida, Rakesh Popat, Jeffrey S.Y. Huang, Anne Yver, Erik Vandendries, Mohamed Elmeliegy, Wei Dong Ma, Douglas W. Sboro (2022). MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma. 40(no. 16 (supplemental)), TPS8068-TPS8068..
5. Cesar Rodriguez, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Ajai Chari, Rebecca Wang Silbermann, Luciano J. Costa, Larry D. Anderson Jr., Nitya Nathwani, Nina Shah, Naresh Bumma, Andrzej J. Jakubowiak, Robert Z. Orlowski, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhee (2022). Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A Post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN. 40(no. 16 (supplemental)), 8011-8011..
6. Doris K. Hansen, Surbhi Sidana, Lauren Peres, Leyla Shune, Douglas W. Sborov, Hamza Hashmi, Mehmet H. Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher J. Ferreri, Aimaz Afrough, Ankit J. Kansagra, Peter M. Voorhees, Melissa Alsina, Joseph McGuirk, Frederick L. Locke, Krina K. Pate (2022). Idecabragene vicleucel (ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. 40(no. 16 (supplemental)), 8042-8042..
7. SaurabhChhabra1Natalie S.Callander2Luciano J.Costa3Jonathan L.Kaufman4Jacob P.Laubach5Douglas W.Sborov6BrandiReeves7CesarRodriguez8AjaiChari9Rebecca W.Silbermann10Larry D.AndersonJr.11NityaNathwani12NinaShah13NareshBumma14Sarah A.Holstein15CaitlinCostello16AndrzejJakubowiak17Tanya M.Wildes18Robert Z.Orlowski19Kenneth H.Shain20Andrew J.Cowan21BhagirathbhaiDholaria22HuilingPei23AnneloreCortoos24SharmilaPatel24J BlakeBartlett25JessicaVermeulen26Thomas S.Lin24Paul G.Richardson27Peter M.Voorhees2 (2021). Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant=Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. 138(Supplement 1), 2852.
8. Zachary D.Crees1Keith E.Stockerl-Goldstein2MichaelRetting3Sarah MLarson4ArpadIlles5GiuseppeMilone6MassimoMartino7PatrickStiff8Douglas W.Sborov9Denise L.Pereira10Ivana N.Micallef11GemmaMoreno Jiménez12GáborMikala13Maria LizPaciello Coronel14UdoHoltick15John W.Hiemenz16Muzaffar H.Qazilbash17Nancy M.Hardy18TahirLatif19IreneGarcía-Cadenas20EllaSorani21LironShemesh-Darvish22AbiVainstein23ShaulKadosh22John F.DiPersio (2021). Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial. 138(Supplement 1), 2849.
9. Zachary D.Crees1Keith E.Stockerl-Goldstein2SarahLarson3ÁrpádIllés4GiuseppeMilone5MassimoMartino6PatrickStiff7Douglas W.Sborov8Denise L.Pereira9Ivana N.Micallef10GemmaMoreno Jiménez11GáborMikala12Maria lizpaciello Coronel13UdoHoltick14John W.Hiemenz15Muzaffar H.Qazilbash16Nancy M.Hardy17TahirLatif18IreneGarcía-Cadenas19AbiVainstein20EllaSorani21IritGliko-Kabir22InbalGoldstein22ShaulKadosh22John F.DiPersio (2021). Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial. 138(Supplement 1), 475.
10. Victoria A.Vardell1Daniel A.Ermann2Srinivas K.Tantravahi3BrianMcClune4Mary NicoleSteinbach5Ghulam RehmanMohyuddin6AmandeepGodara6Douglas W.Sborov (2021). Multiple Myeloma Patients Treated at Academic Centers Have Improved Survival Outcomes. 138(Supplement 1), 1971.
11. Rosalie G. Waller, Michael J. Madsen, John Gardner, Douglas Sborov and Nicola J. Cam (2020). Characterization of quantitative gene-expression dimensions in myeloma tumors. 10.1158/1538-7755.MODPOP19-A40,
12. Hans Chulhee Lee, Adam D. Cohen, Ajai Chari, Malin Hultcrantz, Ajay K. Nooka, Natalie Scott Callander, Attaya Suvannasankha, Ashraf Badros, Edward N. Libby, Suzanne Trudel, Paul G. Richardson, Douglas Weston Sborov, Paula Rodríguez Otero, Sagar Lonial, Eric Zhi, Eric Lewis, Ira Gupta, Joanna Opalinsk (2020). DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment. 10.1200/JCO.2020.38.15_suppl.8519,
13. Rosalie G. Waller, Heidi A. Hanson, Michael J. Madsen, Brian Avery, Douglas Sborov, Nicola J. Cam (2020). Transcriptome Spectra: Agnostic Expression Variables to Empower Genomic Epidemiology Studies. https://doi.org/10.1101/2020.10.06.20206714,
14. Rosalie G. Waller, Heidi A. Hanson, Michael J. Madsen, Brian Avery, Douglas Sborov, Nicola J. Cam (2020). Spectra: Agnostic Expression Variables for Flexible Transcriptome Modeling in Complex Disease. https://doi.org/10.1101/2020.10.06.20206714,
15. Douglas Weston Sborov, Domenico Viola, Ada A Dona, Ajay K. Nooka, Jonathan L. Kaufman, Sagar Lonial, Lawrence Boise, Madhav V. Dhodapkar, Nisha Joseph, Flavia Pichiorri, Craig C. Hofmeiste (2020). Oncolytic virus pelareorep plus carfilzomib phase 1 trial in carfilzomib-refractory patients (NCI 9603): Responses with cytokine storm. 38(15), 1645-1750.
16. Sagar Lonial, Hans Chulhee Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al-Ola A. Abdallah, Natalie Scott Callander, Douglas Weston Sborov, Attaya Suvannasankha, Katja Weisel, Peter Michael Voorhees, Axel Hoos, Eric Zhi, January Baron, Trisha Piontek, Roxanne C. Jewell, Joanna Opalinska, Ira Gupta, Adam D. Cohe (2020). Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). 38(15),
17. Nidhi Sharma, Nita Williams, Ashley E. Rosko, Don M. Benson Jr., Maria Chaudhry, Craig C Hofmeister, Douglas W. Sborov, and Yvone Efebera (1/1/19). Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up [Abstract]. Blood.
18. Craig C Hofmeister, Douglas W. Sborov, Domenico Viola, Ada Dona, Gelard J Nuovo, Don M. Benson Jr., Sagar Lonial, Jonathan L Kaufman, Ajay K Nooka, Leonard Heffner, Madhav V Dhodapkar, and Flavia Pichiorr (2019). Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patient Increases PD-L1 Expression with Clinical Responses.
19. Persaud AK, Li J, Johnson JA, Seligson N, Sborov DW, Duah E, Cho YK, Wang D, Phelps MA, Hofmeister CC, Poi M (2019). XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
20. Peter M. Voorhees, MD, Jonathan L. Kaufman, MD, Jacob P. Laubach, MD, Douglas W. Sborov, MD MSc, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, MD, Rebecca W. Silbermann, MD, Luciano J. Costa, MD PhD, Larry D. Anderson, MD PhD, Nitya Nathwani, MD, Nina D. Shah, MD, Yvonne A. Efebera, MD MPH, Caitlin L. Costello, MD, Andrzej Jakubowiak, MD PhD, Tanya M. Wildes, MD, Robert Z. Orlowski, MD PhD, Kenneth H. Shain, MD PhD, Andrew J. Cowan, MD, Sean Murphy, Yana Lutska, PharmD, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Carla de Boer, Daniela Hoehn, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, M (2019). Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) improves over time in patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM):Griffin Study Update. 653 Myeloma: Therapy Excluding Transplantation,
21. Peter Voorhees Jonathan L. Kaufman Jacob Laubach Douglas Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano Costa Larry Anderson Nitya Nathwani Nina Shah Yvonne Efebera Caitlin Costello Andrzej Jakubowiak Tanya Wildes Robert Z. Orlowski Kenneth H. Shain Andrew Cowan Sean Murphy Yana Lutska Huiling Pei Jon Ukropec Jessica Vermeulen Carla de Boer Daniela Hoehn Thomas Lin Paul G. Richardso (2019). Daratumumab+lenalidomide, bortezomib & dexamethasone improves depth of response in transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. 19(10),
22. Ada Dona', PhD, Domenico Viola, Enrico Caserta, PhD, Francesca Besi, PhD, James F Sanchez, PhD, Guido Marcucci, MD, Jonathan J Keats, PhD, Amrita Y. Krishnan, MD, Matt Coffey, PhD, Douglas W. Sborov, MDMSc, Gerard Nuovo, MD, Craig C Hofmeister, MDMPH, Flavia Pichiorri, Ph (2019). Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma. 652.Myeloma:Pathophysiology and Pre-Clinical Studies, Excluding Therapy,
23. Saad Usmani Chatchada Karanes William I. Bensinger Anita D'Souza Noopur Raje Sascha Tuchman Douglas Sborov Dheepak Kanagavel Franck Dubin Frank Campana Paul G. Richardso (2019). Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study. 19(10),
24. Jacken Waters Reuben Benjamin Stella Bowcock Kirsty Cuthill Sophie Deppe Ana Duran Maestre Douglas Gunning Maj Kazmi Alice Mason Grace Milner Hannah Patrick Carmel Rice Matthew Streetl (2019). Comparing clinical trial data against a real world dataset - progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatment. 19(10),
25. MING J. POI1,2,3¿, JUNAN LI1,4¿, JASMINE A. JOHNSON1,#, YU KYOUNG CHO3, DOUGLAS W. SBOROV5, MITCH A. PHELPS3,4 and CRAIG C. HOFMEISTER (2018). A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients.
26. Greg D Whitehill, BS1,2*, Alicia Chivers, MS1*, Bryan Danielson, PhD1*, Julien SR Tessier, MS1*, Gabriela Hernandez Duran1*, Gabrielle L Bender, BS1*, Douglas W. Sborov, MD, MSc3, Craig C Hofmeister, MD4, James Bradner, MD5, Teru Hideshima, MD, PhD6, Kenneth C. Anderson, MD6 and Gullu Gorgun, PhD (2017). Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment.
27. Tim Luetkens, MD1*, Sara Yousef, PhD1*, Christa Shorter, BSc1*, Srinivas K. Tantravahi, MBBS1, Mary Nicole Steinbach, NP1*, Janet Weidner1*, Douglas W. Sborov, MD, MSc1 and Djordje Atanackovic, MD (2017). In Vivo Vaccination Effect in Clinical Responders to Anti-Myeloma Monoclonal Antibody Isatuximab.
28. Sabarinath Venniyil Radhakrishnan, MBBS, MD1, Tim Luetkens, MD1*, Sara Yousef, PhD1*, Neelam Bhardwaj, PhD1*, Mary Nicole Steinbach, NP1*, Janet Weidner1*, Christa Shorter, BSc1*, Douglas W. Sborov, MD, MSc1 and Djordje Atanackovic, MD (2017). Chimeric Antigen Receptor (CAR) T Cells Specific for CD229: A Potentially Curative Approach for Multiple Myeloma.
29. Cottini F, Sborov DW, Cho YK, Lamprecht M, Tackett K, Li J, Devine SM, Poi M, Phelps MA, Hofmeister C (2016). G-CSF starting day +1 after autologous transplant is safer than day +5 or day +7 in patients with multiple myeloma.
30. Bhatt G, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski SM, Devine SM, Wildes TM, Jones D, Huang Y, Rosko A (2016). A feasibility study of electronic geriatric assesment for real-time morbidity evaluation. 34(15),
31. Hudzik S, Snoad B, Mousa L, Sborov DW, Williams N, Jones D, Hofmeister CC (2015). The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics [Abstract]. Blood, 126(23).
32. Snoad B, Hudzik S, Sborov DW, Williams N, Jones D, Hofmeister CC (2015). The Majority of Myeloma Patients Are Hypogonadal but this is not Associated with High Risk Cytogenetics; also presented as a poster at the 57th American Society of Hematology Annual Meeting, 5-8 December 2015, Orlando, FL [Abstract]. Blood, 126(23).
33. Sborov DW, Pichiorri F, Nuovo JG, Benson DM, Efebera YA, Rosko AE, Hofmeister CC (2015). Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients; also presented as a poster at the 57th American Society of Hematology Annual Meeting, 5-8 December 2015, Orlando, FL [Abstract]. Blood, 126(23).
34. Rosko AE, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski S, Devine SM, Wildes T, Gillahan JE, Huang Y, Burd CE (2015). Geriatric Assessment Metrics are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients; also presented as a poster at the 57th American Society of Hematology Annual Meeting, 5-8 December 2015, Orlando, FL [Abstract]. Blood, 126(23).
35. Rosko AE, Jofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski S, Devine S, Wildes TM, Gillahan J, Jones D, Huang Y (2015). Geriatric assessment metrics are associated with hospital length of stay in pre-bone marrow transplant myeloma patients [Abstract]. Blood, 126(23), 3200.
36. Sborov DW, Pichiorri F, Nuovo JG, Benson DM, Efebera YA, Rosko AE, Hofmeister C (2015). Combination Carfilzomib and the Viral Oncolytic Agent Reolysin in Patients with Relapsed Multiple Myeloma: a Pilot Study Investigating Viral Proliferation; also presented as a poster at the 15th International Myeloma Workshop. 15(Suppl 3), e301.
37. Cho YK, Li J, Wang J, Gao Y, Sborov DW, Lamprecht M, Jukich M, Falk W, Schaaf LJ, Poi M, Hofmeister CC, Phelps M (2015). Pharmacokinetic and Pharmacodynamic Modeling for Personalizing Melphalan Dosing in Multiple Myeloma Patients Receiving Autologous Transplant.
38. Cordero H, Sborov DW, Canella A, Liu Z, Wang J, Radomska H, Stiff A, Cortrill J, Consiglio J, Ni W, Smith E, Efanov A, Rizzotto L, Benson DM, Cascione L, Mo X, Phelps MA, Chan KK, Byrd JC, Grever MR, Hofmeister CC, Pichiorri F (2014). HDAC inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide; also presented as a poster at the 56th American Society of Hematology Annual Meeting, 6-9 December 2014, San Francisco, CA [Abstract]. Blood, 124(21), 3377.
39. Cho YK, Li J, Sborov DW, Wang J, Gao Y, Lamprecht M, Poi M, Phelps MA, Hofmeister CC (2014). Development of a predictive pharmacokinetic and pharmacodynamics model to personalize melphalan dosing in autologous transplant for patients with multiple myeloma; also presented as a poster at the 56th American Society of Hematology Annual Meeting, 6-9 December 2014, San Francisco, CA [Abstract]. Blood, 124(21), 1086.
40. Sborov DW, Lamprecht M, Benson DM, Tackett K, Efebera YA, Rosko AE, Devine SM, Poi M, Phelps M, Hofmeister CC (2014). 2-hour cryotherapy effectively reduces severe mucositis associated with high dose melphalan followed by stem cell rescue: results from a randomized trial; also presented as a poster at the 56th American Society of Hematology Annual Meeting, 6-9 December 2014, San Francisco, CA [Abstract]. Blood, 124(21), 3960.
41. Sborov DW, Marsh L, Yearsley M, Geyer S, Falk W, Devine SM, Hofmeister C (2014). Utility of CMV PCR in the Evaluation of Allograft Recipients Presenting with Diarrhea; also presented as a poster at the 2014 BMT Tandem Meetings, February 26 - March 2, 2014, Grapevine, TX. Biology of blood and marrow transplantation, 20(Suppl 2), S250-1.
42. Sborov DW, Nuovo G, Stiff A, Mace T, Lesinski G, Benson DM, Efebera YA, Rosko A, Pichiorri F, Hofmeister CC (2013). A Phase 1 Trial Of Reolysin Alone In Patients With Refractory Or Relapsed Multiple Myeloma; also presented as a poster at the 55th American Society of Hematology Annual Meeting, 7-10 December 2013, New Orleans, LA [Abstract]. Blood, 122(21), 3208.
43. Stiff A, Badway J, Nuovo G, Sborov D, Smith E, Talabere T, Hofmeister C, Pichiorri F (2013). Understanding The Differential Response Of Multiple Myeloma To Reovirus Treatment; also presented as a poster at the 55th American Society of Hematology Annual Meeting, 7-10 December 2013, New Orleans, LA [Abstract]. Blood, 122(21), 3232.

Other

1. Berndt SI, Vijai J, Benavente Y, Camp NJ, Nieters A, Wang Z, Smedby KE, Kleinstern G, Hjalgrim H, Besson C, Skibola CF, Morton LM, Brooks-Wilson AR, Teras LR, Breeze C, Arias J, Adami HO, Albanes D, Anderson KC, Ansell SM, Bassig B, Becker N, Bhatti P, Birmann BM, Boffetta P, Bracci PM, Brennan P, Brown EE, Burdett L, Cannon-Albright LA, Chang ET, Chiu BCH, Chung CC, Clavel J, Cocco P, Colditz G, Conde L, Conti DV, Cox DG, Curtin K, Casabonne D, De Vivo I, Diepstra A, Diver WR, Dogan A, Edlund CK, Foretova L, Fraumeni JF Jr, Gabbas A, Ghesquières H, Giles GG, Glaser S, Glenn M, Glimelius B, Gu J, Habermann TM, Haiman CA, Haioun C, Hofmann JN, Holford TR, Holly EA, Hutchinson A, Izhar A, Jackson RD, Jarrett RF, Kaaks R, Kane E, Kolonel LN, Kong Y, Kraft P, Kricker A, Lake A, Lan Q, Lawrence C, Li D, Liebow M, Link BK, Magnani C, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Monnereau A, Montalvan R, North KE, Novak AJ, Onel K, Purdue MP, Rand KA, Riboli E, Riby J, Roman E, Salles G, Sborov DW, Severson RK, Shanafelt TD, Smith MT, Smith A, Song KW, Song L, Southey MC, Spinelli JJ, Staines A, Stephens D, Sutherland HJ, Tkachuk K, Thompson CA, Tilly H, Tinker LF, Travis RC, Turner J, Vachon CM, Vajdic CM, Van Den Berg A, Van Den Berg DJ, Vermeulen RCH, Vineis P, Wang SS, Weiderpass E, Weiner GJ, Weinstein S, Doo NW, Ye Y, Yeager M, Yu K, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Ziv E, Sampson J, Chatterjee N, Offit K, Cozen W, Wu X, Cerhan JR, Chanock SJ, Slager SL, Rothman (2023). Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia, 37(10), 2142.
2. Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri (2023). Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget, 14, 837-838.

Video/Film/CD/Web/Podcast

1. D. Sboro (2023). Case Based Roundtable - Challenging Cases of Relapsed/Refractory Multiple Myeloma Co-Moderator - Dr. Douglas Sborov https://event.targetedonc.com/event/e75aef30-ef62-45c3-9f64-00cfb8129940/websitePage:f850481a-22fe-442f-9254-bd15d6d0a859.
2. D Sboro (2022). Your Path to Empowerment Multiple Myeloma, Patient Empowerment Network.
3. D Sboro (2022). Becoming a Partner with Your Healthcare Team - Douglas Sborov - RT Salt Lake City UT, Health Tree Foundation.
4. D Sboro (2022). Douglas Sborov Leads Faculty Discussion | RT Salt Lake City, UT - Health Tree Foundation.
5. D Sboro (2022). The Role of Trust in Managing High-Risk Multiple Myeloma - Our Multiple Myeloma: Greg's Story - Patient Power.
6. D Sboro (2022). The Impact of Multiple Myeloma on Family Life - Patient Power.
7. D Sboro (2022). Path to Empowerment: Multiple Myeloma | Testing. Patient Empowerment Network.
8. D Sboro (2022). ASH 2021: Cellular Therapies in Myeloma. Yale Cancer Center Featuring Noffa Bar.
9. D Sboro (2021). Simple Diagnostic Tests Empowering Multiple Myeloma Patients; BBC Story Works, Connecting the Dots; Skyline-dx .
10. D Sboro (2021). Multiple Myeloma Care During the Pandemic, with Dr. Sborov.
11. D Sboro (2021). Talks with Docs: Douglas Sborov, Multiple Myeloma Director at HCI.
12. D Sboro (2021). Douglas Sborov, MD, on Expanding Access to Multiple Myeloma Clinical Trials, DocWire News.
13. D Sborov, M Steinbac (2021). Doctor and Nurse Practitioner Discuss Myeloma Treatment | Douglas W. Sborov, MD MS & Mary Steinbach APRN Nurse Practitioner, University of Utah/Huntsman Cancer Institute Division of Hematology & Hematologic Malignancies. - Patient Power Newsletter .
14. D Sboro (2021). Is Multiple Myeloma Hereditary? Janssen Oncology, Patient Power.
15. D Sboro (2021). Dr. Sborov on the Toxicities Associated with Novel Therapies in Multiple Myeloma | OncLive.
16. D Sboro (2021). ASH 2021: Bispecific Antibodies for Multiple Myeloma - Patient Power.
17. D Sboro (2021). Dr. Sborov on Mitigating Monoclonal Antibody - Associated Toxicity in Multiple Myeloma - OncLive TV.
18. D Sboro (2021). Dr. Sborov Discusses Expanding Access to MM Clinical Trials. DocuWire News.
19. D Sboro (2021). Dr. Sborov on Managing Bispecific Antibody-Related Adverse Effects in Multiple Myeloma. OncLive.
20. Sborov DW, Hofmeister C (2015). Multiple Myeloma Case Study: High Risk Relapsing MM: Efficacy with retreatment with Immunomodulatory Therapy.
21. Sborov DW, Hofmeister C (2015). Multiple Myeloma Case Study: Refractory MM in high-risk patients: Efficacy with Proteosome Inhibitor Therapy.
22. Sborov DW, Hofmeister C (2014). Multiple Myeloma Case Study: Relapsed MM: Efficacy of Retreatment with Immunomodulatory Therapy.
23. Sborov DW, Hofmeister C (2014). Multiple Myeloma Case Study: Refractory MM: Efficacy of Retreatment with Immunomodulatory Therapy.

Huntsman Cancer Institute News

• Discovery Innovations Fall 2025
• Interdisciplinary Grants Awarded for Cancer-Focused Engineering Projects
• Talks with Docs: Douglas Sborov, Multiple Myeloma Director
• Why I Participate in Employee Giving
• Sticking with the Positive through Multiple Myeloma